GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Cyclically Adjusted PB Ratio

RZLT (Rezolute) Cyclically Adjusted PB Ratio : 0.98 (As of May. 29, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Rezolute Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Rezolute's current share price is $4.02. Rezolute's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $4.09. Rezolute's Cyclically Adjusted PB Ratio for today is 0.98.

The historical rank and industry rank for Rezolute's Cyclically Adjusted PB Ratio or its related term are showing as below:

RZLT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.96
Current: 0.96

During the past years, Rezolute's highest Cyclically Adjusted PB Ratio was 0.96. The lowest was 0.00. And the median was 0.00.

RZLT's Cyclically Adjusted PB Ratio is ranked better than
59.1% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs RZLT: 0.96

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rezolute's adjusted book value per share data for the three months ended in Mar. 2025 was $1.364. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $4.09 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Rezolute Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Rezolute's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rezolute Cyclically Adjusted PB Ratio Chart

Rezolute Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 13.10 1.60 0.45 0.76

Rezolute Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.76 0.93 1.05 0.71

Competitive Comparison of Rezolute's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Rezolute's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rezolute's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rezolute's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rezolute's Cyclically Adjusted PB Ratio falls into.


;
;

Rezolute Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Rezolute's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.02/4.09
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rezolute's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Rezolute's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.364/134.9266*134.9266
=1.364

Current CPI (Mar. 2025) = 134.9266.

Rezolute Quarterly Data

Book Value per Share CPI Adj_Book
201506 18.591 100.684 24.914
201509 13.877 100.392 18.651
201512 7.758 99.792 10.489
201603 2.298 100.470 3.086
201606 12.497 101.688 16.582
201609 10.921 101.861 14.466
201612 9.686 101.863 12.830
201703 9.307 102.862 12.208
201706 8.658 103.349 11.303
201709 7.261 104.136 9.408
201712 3.517 104.011 4.562
201803 0.493 105.290 0.632
201806 -3.187 106.317 -4.045
201809 -5.183 106.507 -6.566
201812 -7.913 105.998 -10.073
201903 -21.415 107.251 -26.941
201906 0.416 108.070 0.519
201909 3.515 108.329 4.378
201912 2.504 108.420 3.116
202003 1.760 108.902 2.181
202006 1.255 108.767 1.557
202009 0.747 109.815 0.918
202012 4.297 109.897 5.276
202103 3.488 111.754 4.211
202106 3.125 114.631 3.678
202109 2.495 115.734 2.909
202112 4.003 117.630 4.592
202203 3.337 121.301 3.712
202206 4.451 125.017 4.804
202209 4.157 125.227 4.479
202212 3.836 125.222 4.133
202303 3.457 127.348 3.663
202306 3.155 128.729 3.307
202309 2.812 129.860 2.922
202312 2.315 129.419 2.414
202403 1.766 131.776 1.808
202406 2.273 132.554 2.314
202409 2.048 133.029 2.077
202412 1.645 133.157 1.667
202503 1.364 134.927 1.364

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rezolute  (NAS:RZLT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Rezolute Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Rezolute's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rezolute Business Description

Industry
Traded in Other Exchanges
N/A
Address
275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Executives
Wladimir Hogenhuis director 60 LEVERONI COURT, NOVATO CA 94949
Nevan C Elam director, 10 percent owner, officer: Chief Executive Officer C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Young-jin Kim director 49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Brian Kenneth Roberts officer: Chief Medical Officer C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Handok, Inc. 10 percent owner 132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Gil M Labrucherie director 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Nerissa Kreher director C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Philippe Fauchet director C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim director C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc. 10 percent owner 700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller officer: VP Finance & CAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young Chul Sung director 101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola officer: Chief Financial Officer 111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp 10 percent owner 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch director C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089